KLRS

Kalaris Therapeutics
$3.58
−$0.15 (−4.02%)Jul 27, 2026
0.7PoorMoatMint rating

MoatMint rates Kalaris Therapeutics (KLRS) 0.7 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 1.0 out of 10.

Key metrics

The numbers that frame KLRS today
Market cap
$85.18M
P/E (TTM)
-1.9
EV / FCF
-1.2
ROIC
-155.9%
Div yield
0%
Debt / equity
0.0
52wk Low
$2.14
52wk High
$11.88

KLRS stock rating

How KLRS scores on quality, value, growth, momentum and financial health
0.7out of 10
Low overallNeutral business, expensive priceTop 93% of ~5,000 US stocks
QualityPoor1.0/10
GrowthFair3.0/10
MomentumFair3.7/10
ValuePoor0.4/10
Financial HealthFair2.1/10

Growth

Revenue and earnings trend for KLRS
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about KLRS
Is Kalaris Therapeutics a good buy?
No. Kalaris Therapeutics has poor quality and weak momentum. Both signals point to a weaker setup. Growth looks weak. That could put pressure on the long-term business case. We think Kalaris Therapeutics is selling at a very high price.
What is the market capitalization of KLRS?
Kalaris Therapeutics's market capitalization is $85.18M.
What is the P/E ratio for KLRS stock?
Kalaris Therapeutics's current P/E ratio is -1.9.
What is the 52-week high for KLRS stock?
The 52-week high for Kalaris Therapeutics is $11.88. The current close of $3.58 is 69.9% below that high.
What is the 52-week low for KLRS stock?
The 52-week low for Kalaris Therapeutics is $2.14. The current close of $3.58 is 67.3% above that low.
Does KLRS stock pay dividends?
Kalaris Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for KLRS?
Kalaris Therapeutics's Debt / Equity ratio is 0.02.